<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=1200, user-scalable=yes, initial-scale=0.4, minimum-scale=0.1">
    <title>Bromazepam - Complete Profile</title>
    <link rel="stylesheet" href="/Dyo-s-Dubious-Domain/style.css">
    <link rel="icon" type="image/svg+xml" href="/Dyo-s-Dubious-Domain/assets/logo.svg">
    <script>
        // Set base path for JavaScript files to use
        window.SITE_BASE_PATH = '/Dyo-s-Dubious-Domain/';
        
        // Force desktop behavior by overriding mobile detection
        window.isMobile = false;
        window.isDesktop = true;
        
        // Override any mobile detection functions
        if (window.matchMedia) {
            const originalMatchMedia = window.matchMedia;
            window.matchMedia = function(query) {
                // Force desktop media queries to always match for min-width
                // and mobile queries to never match
                if (query.includes('max-width') && (query.includes('768px') || query.includes('480px'))) {
                    return { matches: false, addListener: function() {}, removeListener: function() {} };
                }
                if (query.includes('min-width')) {
                    return { matches: true, addListener: function() {}, removeListener: function() {} };
                }
                return originalMatchMedia.call(this, query);
            };
        }
    </script>
</head>

<body class="
  
  
  
  ">
    <header class="page-header">
  <div class="container">
    <div class="page-header__content">
      <div class="logo-container">
        <a href="/Dyo-s-Dubious-Domain/" class="site-title">Dyo's Dubious Domain</a>
      </div>
      
      <nav>
        <ul role="list" class="nav-list flex-group">
          <li>
            <a href="/Dyo-s-Dubious-Domain/">Home</a>
          </li>
          <li>
            <a href="/Dyo-s-Dubious-Domain/dyos-domain/">Dyo's Domain</a>
          </li>
          <li>
            <a href="/Dyo-s-Dubious-Domain/about/">About</a>
          </li>
          <li>
            <a href="/Dyo-s-Dubious-Domain/profile/">My Profile</a>
          </li>
         
        </ul>
      </nav>
    </div>
    
    <!-- Search Bar - Now underneath header -->
    <div class="search-container">
      <input type="text" id="search-input" placeholder="Search substances..." class="search-input" />
      <div id="search-results" class="search-results" style="display: none;"></div>
    </div>
  </div>
</header>

    <main>
      
<div class="substance-profile-header">
  <div class="container">
    <nav class="breadcrumb">
      <a href="/dyos-domain/">Dyo's Domain</a> ‚ÜÅE<a href="/dyos-domain/depressants/">Depressants</a> ‚ÜÅE<span>Bromazepam</span>
    </nav>
    
    <div class="substance-hero">
      <div class="substance-info">
        <h1>üíä Bromazepam</h1>
        <h2 class="chemical-name">7-bromo-1,3-dihydro-5-(2-pyridyl)-2H-1,4-benzodiazepin-2-one</h2>
          
        <!-- Add to Profile Button -->
        <button id="add-to-profile-btn" class="add-to-profile-btn not-in-profile" 
                data-substance="Bromazepam" 
                data-category="Depressants" 
                data-chemical="7-bromo-1,3-dihydro-5-(2-pyridyl)-2H-1,4-benzodiazepin-2-one">
          + Add to My Profile
        </button>
        
        <div class="alternative-names">
          <h3>Alternative Names & Slang</h3>
          <div class="names-grid">
            <div class="name-category">
              <h4>Brand Names</h4>
              <span>Lexotan</span> ‚Ä¢ <span>Lectopam</span> ‚Ä¢ <span>Brazepam</span> ‚Ä¢ <span>Compendium</span>
            </div>
            <div class="name-category">
              <h4>International Names</h4>
              <span>Lexotanil</span> ‚Ä¢ <span>Durazanil</span> ‚Ä¢ <span>Somalium</span> ‚Ä¢ <span>Normoc</span>
            </div>
            <div class="name-category">
              <h4>Street Names</h4>
              <span>Benzos</span> ‚Ä¢ <span>Bromas</span> ‚Ä¢ <span>Lex</span> ‚Ä¢ <span>Anxiety pills</span>
            </div>
            <div class="name-category">
              <h4>Chemical Names</h4>
              <span>7-bromo-5-(pyridin-2-yl)-1,3-dihydro-1,4-benzodiazepin-2-one</span>
            </div>
          </div>
        </div>
        
        <div class="substance-meta-large">
          <span class="category benzodiazepine">Benzodiazepine</span>
          <span class="legal-status schedule-4">Schedule IV</span>
          <span class="duration medium">8-20 hours</span>
        </div>
      </div>
      
      <div class="substance-visual">
        <div class="substance-image">
          <img src="/Dyo-s-Dubious-Domain/assets/substances/bromazepam.jpg" alt="Bromazepam tablets in various forms" class="substance-photo">
        </div>
        <div class="molecule-structure">
          <div class="structure-placeholder">
            <p>üß¨ C‚ÇÅ‚ÇÑH‚ÇÅÔøΩEBrN‚ÇÉO</p>
            <p>MW: 316.15 g/mol</p>
          </div>
        </div>
      </div>
    </div>
  </div>
</div>

<div class="container">
  
  <div class="profile-grid">
    
    <div class="profile-section identification">
      <h3>üîç Physical Identification</h3>
      <div class="identification-info">
        <div class="pure-form">
          <h4>Legitimate Pharmaceutical Forms</h4>
          <ul>
            <li><strong>1.5mg tablets:</strong> Small white, round tablets, often scored</li>
            <li><strong>3mg tablets:</strong> White or light pink, round or oval tablets</li>
            <li><strong>6mg tablets:</strong> White, round or oval, may be scored</li>
            <li><strong>Generic versions:</strong> Various colors depending on manufacturer</li>
            <li><strong>Capsules:</strong> Less common, gelatin caps with powder</li>
            <li><strong>Sublingual:</strong> Dissolving tablets for faster onset</li>
          </ul>
        </div>
        
        <div class="regional-variations">
          <h4>Regional Presentations</h4>
          <ul>
            <li><strong>European markets:</strong> Lexotan brand, distinctive packaging</li>
            <li><strong>Latin America:</strong> Widely available, various generic brands</li>
            <li><strong>Asia:</strong> Common anxiety medication, different dosage forms</li>
            <li><strong>Blister packs:</strong> Standard pharmaceutical packaging</li>
          </ul>
        </div>
        
        <div class="identification-tips">
          <h4>üîç Identification Features</h4>
          <p><strong>Authentic tablets:</strong> Professional pharmaceutical appearance with clear imprints</p>
          <p><strong>Common imprints:</strong> Manufacturer codes, dosage markings, score lines</p>
          <p><strong>Taste:</strong> Slightly bitter, typical benzodiazepine taste</p>
          <p><strong>Texture:</strong> Smooth, consistent pharmaceutical coating</p>
        </div>
      </div>
    </div>
    
    <div class="profile-section dosage">
      <h3>üíä Dosage Guidelines</h3>
      <div class="dosage-chart">
        <div class="dose-range threshold">
          <span class="range-label">Threshold</span>
          <span class="dose-amount">0.5-1mg</span>
          <div class="dose-bar"></div>
        </div>
        <div class="dose-range light">
          <span class="range-label">Light</span>
          <span class="dose-amount">1-3mg</span>
          <div class="dose-bar"></div>
        </div>
        <div class="dose-range common">
          <span class="range-label">Common</span>
          <span class="dose-amount">3-6mg</span>
          <div class="dose-bar"></div>
        </div>
        <div class="dose-range strong">
          <span class="range-label">Strong</span>
          <span class="dose-amount">6-12mg</span>
          <div class="dose-bar"></div>
        </div>
        <div class="dose-range heavy">
          <span class="range-label">Heavy</span>
          <span class="dose-amount">12mg+</span>
          <div class="dose-bar"></div>
        </div>
      </div>
      
      <div class="dosage-details">
        <h4>Medical Dosage Guidelines</h4>
        <ul>
          <li><strong>Anxiety disorders:</strong> 3-18mg daily in divided doses</li>
          <li><strong>Initial therapy:</strong> Start with 1.5-3mg BID or TID</li>
          <li><strong>Maintenance:</strong> 6-12mg daily, adjusted to response</li>
          <li><strong>Elderly patients:</strong> Reduce dose by 50%, start with 1.5mg</li>
          <li><strong>Sleep disorders:</strong> 1.5-3mg at bedtime</li>
          <li><strong>Panic episodes:</strong> 3-6mg as needed</li>
        </ul>
      </div>
      
      <div class="duration-info">
        <h4>Duration & Timing</h4>
        <ul>
          <li><strong>Onset:</strong> 30-60 minutes oral administration</li>
          <li><strong>Peak effects:</strong> 1-4 hours after ingestion</li>
          <li><strong>Duration:</strong> 8-20 hours (long-acting)</li>
          <li><strong>Half-life:</strong> 10-20 hours (intermediate elimination)</li>
          <li><strong>Steady state:</strong> Achieved after 3-5 days of regular dosing</li>
        </ul>
      </div>
      
      <p class="dosage-note"><strong>Gentle Profile:</strong> Bromazepam has a smoother onset and longer duration than alprazolam, making it less prone to abuse but still requiring careful dosing.</p>
    </div>

    <div class="profile-section effects">
      <h3>‚ú® Effects Profile</h3>
      
      <div class="effects-timeline">
        <h4>Timeline</h4>
        <div class="timeline-item">
          <span class="time">T+0:30-1:00</span>
          <span class="effect">Onset - gradual relaxation, anxiety reduction</span>
        </div>
        <div class="timeline-item">
          <span class="time">T+1:00-4:00</span>
          <span class="effect">Peak - maximum anxiolytic effects</span>
        </div>
        <div class="timeline-item">
          <span class="time">T+4:00-12:00</span>
          <span class="effect">Plateau - sustained calming effects</span>
        </div>
        <div class="timeline-item">
          <span class="time">T+12:00-24:00</span>
          <span class="effect">Offset - gradual return to baseline</span>
        </div>
      </div>

      <div class="effects-categories">
        <div class="effect-category positive">
          <h4>‚úÅETherapeutic Effects</h4>
          <ul>
            <li>Smooth anxiety relief</li>
            <li>Reduced panic symptoms</li>
            <li>Muscle relaxation</li>
            <li>Improved sleep quality</li>
            <li>Emotional stabilization</li>
            <li>Reduced physical tension</li>
            <li>Anticonvulsant properties</li>
          </ul>
        </div>
        
        <div class="effect-category negative">
          <h4>‚ùÅESide Effects</h4>
          <ul>
            <li>Daytime sedation</li>
            <li>Cognitive impairment</li>
            <li>Memory problems (mild)</li>
            <li>Motor coordination issues</li>
            <li>Dizziness and fatigue</li>
            <li>Emotional blunting</li>
            <li>Physical dependence risk</li>
          </ul>
        </div>
      </div>

      <div class="unique-characteristics">
        <h4>üåü Unique Characteristics</h4>
        <ul>
          <li><strong>Smoother profile:</strong> Less euphoric than alprazolam, lower abuse potential</li>
          <li><strong>Long duration:</strong> Provides sustained anxiety relief throughout the day</li>
          <li><strong>Less rebound:</strong> Minimal rebound anxiety due to longer half-life</li>
          <li><strong>Stable effects:</strong> Consistent anxiolytic action without dramatic peaks</li>
          <li><strong>Lower amnesia risk:</strong> Less memory impairment than short-acting benzos</li>
        </ul>
      </div>
    </div>

    <div class="profile-section pharmacology">
      <h3>üß† Pharmacology & Neuroscience</h3>
      <div class="pharma-details">
        <h4>Primary Mechanism of Action</h4>
        <p>Bromazepam is a positive allosteric modulator of GABA-A receptors, binding to the benzodiazepine site to enhance GABAergic inhibition. Its pyridyl substitution provides unique pharmacological properties, including anxio-selective effects with less sedation than classical benzodiazepines. The bromine substitution at position 7 contributes to its intermediate duration of action.</p>
        
        <h4>Detailed Receptor Pharmacology</h4>
        <div class="receptor-table">
          <div class="receptor-row">
            <span class="receptor-name"><strong>GABA-A Œ±1Œ≤2Œ≥2</strong></span>
            <span class="affinity">Moderate affinity</span>
            <span class="function">Mild sedation, some motor impairment</span>
          </div>
          <div class="receptor-row">
            <span class="receptor-name"><strong>GABA-A Œ±2Œ≤2Œ≥2</strong></span>
            <span class="affinity">High affinity</span>
            <span class="function">Primary anxiolytic effects, muscle relaxation</span>
          </div>
          <div class="receptor-row">
            <span class="receptor-name"><strong>GABA-A Œ±3Œ≤2Œ≥2</strong></span>
            <span class="affinity">Moderate affinity</span>
            <span class="function">Anxiolytic, muscle relaxant properties</span>
          </div>
          <div class="receptor-row">
            <span class="receptor-name"><strong>GABA-A Œ±5Œ≤2Œ≥2</strong></span>
            <span class="affinity">Low affinity</span>
            <span class="function">Minimal cognitive impairment</span>
          </div>
          <div class="receptor-row">
            <span class="receptor-name"><strong>Peripheral BDZ receptors</strong></span>
            <span class="affinity">Moderate binding</span>
            <span class="function">Anti-inflammatory, neuroprotective effects</span>
          </div>
        </div>

        <h4>Metabolism & Pharmacokinetics</h4>
        <div class="metabolism-details">
          <p><strong>Absorption:</strong> Complete oral absorption, peak levels 1-4 hours</p>
          <p><strong>Bioavailability:</strong> 60-80% oral (good bioavailability)</p>
          <p><strong>Half-life:</strong> 10-20 hours (intermediate elimination)</p>
          <p><strong>Protein binding:</strong> 70% bound to plasma proteins</p>
          <p><strong>Distribution:</strong> Wide tissue distribution, crosses blood-brain barrier</p>
          <p><strong>Metabolism:</strong> Hepatic via oxidation and glucuronidation</p>
        </div>

        <h4>Metabolic Pathway Details</h4>
        <div class="metabolism-pathways">
          <p><strong>Phase I metabolism:</strong> Hydroxylation to 3-hydroxybromazepam (inactive)</p>
          <p><strong>Phase II metabolism:</strong> Glucuronidation of hydroxy metabolites</p>
          <p><strong>Excretion:</strong> Primarily renal as conjugated metabolites</p>
          <p><strong>No active metabolites:</strong> Unlike diazepam, no long-acting metabolites</p>
          <p><strong>CYP involvement:</strong> Minimal CYP enzyme interaction</p>
        </div>

        <h4>Comparative Pharmacology</h4>
        <ul>
          <li><strong>vs. Alprazolam:</strong> Longer acting, less euphoric, lower abuse potential</li>
          <li><strong>vs. Diazepam:</strong> No active metabolites, more anxio-selective</li>
          <li><strong>vs. Lorazepam:</strong> Longer duration, less amnestic</li>
          <li><strong>Unique properties:</strong> Pyridyl ring provides selective anxiolysis</li>
          <li><strong>Therapeutic index:</strong> Good separation between therapeutic and toxic doses</li>
        </ul>
      </div>
    </div>

    <div class="profile-section safety">
      <h3>‚ö†ÔøΩEÔøΩESafety & Harm Reduction</h3>
      
      <div class="safety-grid">
        <div class="safety-item critical">
          <h4>üö® Critical Warnings</h4>
          <ul>
            <li><strong>Respiratory depression:</strong> Dangerous with alcohol or other depressants</li>
            <li><strong>Physical dependence:</strong> Can develop with regular long-term use</li>
            <li><strong>Withdrawal syndrome:</strong> Requires medical supervision to discontinue</li>
            <li><strong>Driving impairment:</strong> Affects reaction time and judgment</li>
          </ul>
        </div>
        
        <div class="safety-item precautions">
          <h4>üõ°ÔøΩEÔøΩEPrecautions</h4>
          <ul>
            <li>Avoid alcohol and other CNS depressants</li>
            <li>Use lowest effective dose for shortest duration</li>
            <li>Gradually taper when discontinuing</li>
            <li>Monitor for tolerance development</li>
            <li>Avoid abrupt cessation after regular use</li>
            <li>Be cautious with elderly patients</li>
          </ul>
        </div>
      </div>

      <div class="contraindications">
        <h4>üö´ Contraindications</h4>
        <p><strong>Absolute contraindications:</strong> Acute narrow-angle glaucoma, severe respiratory depression, severe hepatic impairment, known benzodiazepine hypersensitivity.</p>
        <p><strong>Relative contraindications:</strong> Sleep apnea, chronic respiratory disease, pregnancy, breastfeeding, substance abuse history.</p>
      </div>

      <div class="elderly-considerations">
        <h4>üë¥ Elderly Patients</h4>
        <p><strong>Increased sensitivity:</strong> Elderly patients require 50% dose reduction due to decreased metabolism and increased CNS sensitivity. Higher risk of falls, confusion, and paradoxical reactions.</p>
      </div>
    </div>

    <div class="profile-section interactions">
      <h3>‚öóÔ∏ÅEDrug Interactions</h3>
      
      <div class="interaction-levels">
        <div class="interaction dangerous">
          <h4>üî¥ Dangerous</h4>
          <ul>
            <li><strong>Alcohol:</strong> Severe CNS depression, respiratory depression</li>
            <li><strong>Opioids:</strong> Life-threatening respiratory depression</li>
            <li><strong>Barbiturates:</strong> Additive CNS depression</li>
            <li><strong>Other benzodiazepines:</strong> Compounded sedative effects</li>
          </ul>
        </div>
        
        <div class="interaction risky">
          <h4>üü° Significant</h4>
          <ul>
            <li><strong>Antipsychotics:</strong> Increased sedation and motor impairment</li>
            <li><strong>Antihistamines:</strong> Enhanced drowsiness</li>
            <li><strong>Muscle relaxants:</strong> Additive muscle relaxation</li>
            <li><strong>Sleep medications:</strong> Dangerous oversedation</li>
          </ul>
        </div>
        
        <div class="interaction caution">
          <h4>üü† Monitor</h4>
          <ul>
            <li><strong>Antacids:</strong> May delay absorption but not reduce efficacy</li>
            <li><strong>Cimetidine:</strong> May increase bromazepam levels</li>
            <li><strong>Oral contraceptives:</strong> May slightly increase effects</li>
            <li><strong>Theophylline:</strong> May antagonize benzodiazepine effects</li>
          </ul>
        </div>
      </div>
      
      <div class="interaction-advantages">
        <h4>üí° Interaction Advantages</h4>
        <p><strong>Fewer CYP interactions:</strong> Unlike alprazolam, bromazepam has minimal cytochrome P450 interactions, making it safer with other medications that affect these enzymes.</p>
      </div>
    </div>

    <div class="profile-section legal">
      <h3>‚öñÔ∏ÅELegal Status</h3>
      <div class="legal-info">
        <div class="legal-jurisdictions">
          <div class="jurisdiction">
            <h4>ÔøΩEÔøΩE United States</h4>
            <p><strong>Schedule IV</strong> - Controlled substance, prescription required. Limited availability, not commonly prescribed compared to other benzodiazepines.</p>
          </div>
          <div class="jurisdiction">
            <h4>ÔøΩEÔøΩE United Kingdom</h4>
            <p><strong>Class C</strong> - Prescription only medicine. Available but less commonly prescribed than diazepam or lorazepam.</p>
          </div>
          <div class="jurisdiction">
            <h4>ÔøΩEÔøΩE European Union</h4>
            <p><strong>Prescription Medicine</strong> - Widely available across EU countries, particularly popular in Southern Europe.</p>
          </div>
          <div class="jurisdiction">
            <h4>ÔøΩEÔøΩE Brazil</h4>
            <p><strong>Controlled Substance</strong> - Commonly prescribed anxiety medication, requires prescription and tracking.</p>
          </div>
        </div>
        
        <div class="availability-notes">
          <h4>üåç Global Availability</h4>
          <p>Bromazepam is more widely available outside the United States, where it's commonly prescribed in Europe, Latin America, and Asia. It's considered a first-line anxiety treatment in many countries.</p>
        </div>
      </div>
    </div>

    <div class="profile-section history">
      <h3>üìö History & Culture</h3>
      
      <div class="history-timeline">
        <div class="history-event">
          <span class="year">1963</span>
          <p>First synthesized by Leo Sternbach at Hoffmann-La Roche</p>
        </div>
        <div class="history-event">
          <span class="year">1970</span>
          <p>Introduced to European markets as Lexotan</p>
        </div>
        <div class="history-event">
          <span class="year">1975</span>
          <p>Becomes widely prescribed anxiety medication in Europe</p>
        </div>
        <div class="history-event">
          <span class="year">1980s</span>
          <p>Expands to Latin American and Asian markets</p>
        </div>
        <div class="history-event">
          <span class="year">1990s</span>
          <p>Generic versions become available worldwide</p>
        </div>
        <div class="history-event">
          <span class="year">2000s</span>
          <p>Remains popular alternative to shorter-acting benzos</p>
        </div>
      </div>

      <div class="cultural-impact">
        <h4>Cultural Impact</h4>
        <p>Bromazepam represents the "gentler" benzodiazepine approach - providing effective anxiety relief without the dramatic highs and lows associated with shorter-acting alternatives. It's particularly valued in cultures that prefer steady, long-lasting medication effects over rapid-onset options.</p>
      </div>
    </div>

    <div class="profile-section research">
      <h3>üî¨ Current Research</h3>
      
      <div class="research-areas">
        <div class="research-item">
          <h4>Anxiety Disorders</h4>
          <p>Ongoing studies comparing bromazepam's efficacy and safety profile with newer anxiety treatments, including SSRIs and SNRIs for long-term management.</p>
        </div>
        
        <div class="research-item">
          <h4>Elderly Populations</h4>
          <p>Research into optimal dosing strategies for elderly patients, focusing on maintaining efficacy while minimizing cognitive impairment and fall risk.</p>
        </div>
        
        <div class="research-item">
          <h4>Withdrawal Protocols</h4>
          <p>Development of improved tapering schedules for long-term bromazepam users, minimizing withdrawal symptoms during discontinuation.</p>
        </div>
        
        <div class="research-item">
          <h4>Cognitive Effects</h4>
          <p>Investigation of bromazepam's impact on memory and cognitive function compared to other benzodiazepines, particularly in long-term use.</p>
        </div>
      </div>
    </div>

  </div>

  <div class="substance-resources">
    <h3>üìñ Additional Resources</h3>
    <div class="resources-grid">
      <div class="resource-item">
        <h4>Medical Information</h4>
        <ul>
          <li><a href="https://www.drugs.com/">Drugs.com</a> - Comprehensive medication information</li>
          <li><a href="https://www.mayoclinic.org/">Mayo Clinic</a> - Medical guidance and safety</li>
          <li><a href="https://medlineplus.gov/">MedlinePlus</a> - NIH health information</li>
        </ul>
      </div>
      
      <div class="resource-item">
        <h4>Support & Treatment</h4>
        <ul>
          <li><a href="https://www.benzowithdrawal.com/">Benzo Withdrawal</a> - Support community</li>
          <li><a href="https://www.ashtonmanual.org/">The Ashton Manual</a> - Withdrawal guidance</li>
          <li><a href="https://www.samhsa.gov/">SAMHSA</a> - Treatment locator</li>
        </ul>
      </div>
      
      <div class="resource-item">
        <h4>Safety Resources</h4>
        <ul>
          <li><a href="https://www.fda.gov/">FDA</a> - Drug safety information</li>
          <li><a href="https://www.poison.org/">Poison Control</a> - Emergency assistance</li>
          <li><a href="https://www.ismp.org/">ISMP</a> - Medication safety practices</li>
        </ul>
      </div>
    </div>
  </div>

</div>


    </main>
     <div class="footer-divider"></div>
<footer class="site-footer">
  
</footer>




<footer class="site-footer">
  
  </svg>
    <img src="/Dyo-s-Dubious-Domain/assets/logo.svg" alt="My Logo" class="logo">
     <p>¬© 2025 Uwaniumnya. Highly Illegal.</p>
  </footer>

  

    <!-- Search Scripts -->
    <script src="/Dyo-s-Dubious-Domain/js/lunr.min.js"></script>
    <script src="/Dyo-s-Dubious-Domain/assets/js/search.js"></script>
    <script src="/Dyo-s-Dubious-Domain/assets/js/substance-integration.js"></script>
    
    <!-- Only load profile.js on profile page -->
    
</body>
</html>